Enveric Biosciences, INC

Enveric Biosciences reported second quarter 2026 financial results and provided a corporate update, highlighting advancements in its EB-003 development program and securing new patents.

Enveric Biosciences has filed a prospectus supplement to sell up to $2.425 million in common stock through an existing At-The-Market (ATM) facility.

Enveric Biosciences shareholders approved key governance proposals, including a reverse stock split and authorized share increase, at the 2026 Annual Meeting.

Enveric Biosciences reported Q1 2026 financial results, highlighting progress in its lead drug candidate EB-003 development and a strengthened IP portfolio, alongside a net loss of $1.6 million.

Enveric Biosciences announced its fourth quarter and full-year 2025 financial results, highlighting positive preclinical data for its lead drug candidate EB-003 and strengthening its intellectual property portfolio.

Enveric Biosciences, Inc. filed a prospectus supplement to register an additional $1.346 million in common stock shares for its At-The-Market offering.

Enveric Biosciences reports Q1 2026 results, highlighting progress on lead candidate EB-003 and a recent capital raise, while addressing ongoing liquidity concerns.

Enveric Biosciences reports continued losses and substantial doubt about its ability to continue as a going concern, despite recent capital raises and Nasdaq compliance.

Enveric Biosciences reported an increased net loss for the second quarter and first half of 2025, driven by higher research and development expenses, while raising capital through equity offerings.

Enveric Biosciences reports a net loss of $2.18 million for the first quarter of 2025, alongside updates on its drug development programs and recent financing activities.

Enveric Biosciences reports a net loss of $2.08 million for the third quarter of 2024, alongside ongoing efforts to secure additional funding and maintain Nasdaq listing compliance.

Enveric Biosciences reported its second quarter 2024 results, highlighting ongoing losses and substantial doubt about its ability to continue as a going concern, while also detailing progress in its clinical programs and financial activities.

Enveric Biosciences, a biotechnology company, reported substantial doubt about its ability to continue as a going concern despite recent capital raises, as it focuses on preclinical development of its lead neuroplastogen candidate, EB-003.

Enveric Biosciences reports its 10-K filing, highlighting ongoing losses and substantial doubt about its ability to continue as a going concern, despite advancements in its neuroplastogenic therapeutic pipeline.

Enveric Biosciences has adopted a comprehensive Corporate Code of Conduct and Ethics and Whistleblower Policy to ensure ethical business practices and provide a confidential reporting mechanism for violations.

Enveric Biosciences' Chief Financial Officer, Kevin Michael Coveney, acquired 133,333 restricted stock units on June 1, 2026, as part of his compensation plan.

Enveric Biosciences reports a significant grant of restricted stock units to CEO Joseph Edward Tucker, with vesting over four years.

Director Frank Pasqualone acquired 18,518 shares of Enveric Biosciences common stock through a restricted stock grant.

Director Michael D. Webb acquired 18,518 shares of Enveric Biosciences, Inc. common stock through a restricted stock grant.

Enveric Biosciences, Inc. Director Marcus Schabacker reported the acquisition of 18,518 shares of common stock on June 1, 2026, under the company's 2020 Long-Term Incentive Plan.

Director George A. Kegler acquired 18,518 shares of Enveric Biosciences, Inc. common stock through a restricted stock grant.

Enveric Biosciences announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, a reverse stock split, and an increase in authorized shares.

Enveric Biosciences, Inc. calls a special meeting to seek stockholder approval for a reverse stock split, an increase in authorized shares, and the issuance of shares related to a recent warrant inducement transaction.

Enveric Biosciences has filed a definitive proxy statement with the SEC.

Enveric Biosciences is asking stockholders to approve a conditional reverse stock split to address potential future bid price deficiencies and maintain its Nasdaq listing.

Enveric Biosciences is asking shareholders to approve a reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.

Enveric Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on May 28, 2024, to elect directors, vote on executive compensation, ratify the appointment of the independent auditor, and conduct an advisory vote on the frequency of future executive compensation votes.

Enveric Biosciences has filed an amendment to its S-1 registration statement, primarily to include updated exhibits related to its financial and legal agreements.

Enveric Biosciences is seeking to raise capital through an offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants.

Enveric Biosciences is offering shares of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants, to raise capital for product development and general corporate purposes.

Enveric Biosciences has filed a registration statement for the resale of up to 4.9 million shares of its common stock by Lincoln Park Capital Fund, potentially generating gross proceeds of $2.45 million.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Enveric Biosciences, Inc. common stock.

A filing reveals Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri collectively hold a 2.93% stake in Enveric Biosciences, Inc. through warrant exercises.

Lind Global Fund III LP and associated parties have filed a Schedule 13G reporting a 7.87% beneficial ownership stake in Enveric Biosciences, Inc. through warrant holdings.

Lind Global Fund III LP and affiliates reported a 9.99% passive beneficial ownership stake in Enveric Biosciences, Inc., including common stock and warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Enveric Biosciences, Inc. common stock.

AdvisorShares Trust has reported a 1.66% beneficial ownership stake in Enveric Biosciences, Inc., holding 16,974 shares of common stock.